CAMBRIDGE, MA, hC Bioscience, a company developing first-in-class tRNA-based therapeutics, announced an extension of $16 million to its Series A funding round.
hC Bioscience, a company developing first-in-class tRNA-based therapeutics targeting protein dysfunction in genetically defined diseases, announced an extension of $16 million to its Series A funding round, bringing the total raised to $40 million. Taiho Ventures and Panacea Venture joined existing investors, ARCH Venture Partners, Takeda Ventures and 8VC.
(c) by Massinvestor, Inc. For contact info, please check out our
about page.
